| Title |
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study
|
|---|---|
| Published in |
PLOS ONE, March 2013
|
| DOI | 10.1371/journal.pone.0058438 |
| Pubmed ID | |
| Authors |
Christian Wolf, Jagdev Sidhu, Christian Otoul, Dexter L. Morris, Jennifer Cnops, Jorg Taubel, Barbara Bennett |
| Abstract |
Lymphocyte inhibition by antagonism of α4 integrins is a validated therapeutic approach for relapsing multiple sclerosis (RMS). |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 40 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 17% |
| Student > Master | 5 | 12% |
| Researcher | 5 | 12% |
| Other | 4 | 10% |
| Unspecified | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 14 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 24% |
| Agricultural and Biological Sciences | 4 | 10% |
| Nursing and Health Professions | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Unspecified | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 16 | 38% |